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Abstract
Gastric cancers are the second most common malignancy in the world and represent a major burden to all
societies even though the incidence of disease is decreasing in the industrialized world. The aetiology of the
disease is complex and is believed to be primarily due to environmental factors but a small proportion of cases
are recognised as being associated with genetic factors. Two inherited forms of stomach cancer have been
identified, one which is associated with familial clusterings of stomach cancer and the other being a subgroup
of families that belong to hereditary non polyposis colorectal cancer (or Lynch syndrome). In this report we
present a small nuclear family which is unusual in that there is a clustering of malignancy which includes stomach
cancer, colorectal cancer and chordoma. Genetic analysis failed to reveal any causative mutation in genes
associated with HNPCC or in E-cadherin. Together, the clinical picture in this family may indicate that other
genetic factors are behind this family’s clustering of malignancy. 
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Introduction
Gastric cancers represent the second most common
malignancy worldwide although the incidence of
disease appears to be diminishing in the industrialized
world. Gastric cancers are morphologically
heterogeneous with three types; diffuse gastric cancer,
a glandular (or intestinal) type and a mixture of diffuse
and intestinal disease. 
The causes of gastric cancer are both environmental
and genetic or a mixture of both. Relatively recently
a definitive genetic cause of gastric cancer (mutations
in the E-cadherin gene) has been identified, first in
a large New Zealand Maori kindred [1] and
subsequently in other gastric families [2]. Patients
harbouring mutations in the E-cadherin gene tend to
present with diffuse disease whereas no genetic factors
have been implicated in familial aggregations of
intestinal gastric cancer. 
An alternative genetic cause of stomach cancer in
association with a variety of other epithelial cancers is
hereditary non polyposis colorectal cancer (HNPCC). This
entity is characterized by early onset colorectal cancer
and a variety of other epithelial malignancies including
endometrial cancer and stomach cancer. The genetic
basis of this condition is a breakdown of DNA mismatch
repair due to mutations in genes controlling this process.
Currently four genes have been isolated and associated
with HNPCC, hMLH1, hMSH2, hMSH6 and hPMS2.
Both hMSH2 and hMSH6 reside on chromosome 2,
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hMLH1 is on chromosome 3 and hPMS2 is on
chromosome 7 (for review see Niessen et al 2004 [3]). 
Chordomas are rare slow growing bone tumours that
are believed to arise out of notochord remnants [3]. They
tend to occur at the base of the skull and have a relatively
benign histological appearance. Despite their benign
appearance chordomas have infiltrative properties that
are difficult to control. There is a slight preponderance
for males to be affected with an overall male to female
ratio of about 1.7:1. The preponderance of males
becomes more striking in patients with sacral chordomas
where the male to female ratio approaches 3:1. Little is
known about the molecular basis of chordomas, as there
appears to be no gross chromosomal abnormality or any
other distinct distinguishing feature. Two genetic loci have
been identified. The first indication of a genetic basis for
chordoma came from linkage studies that revealed
a gene locus on chromosome 1 [4]. A second locus was
identified in a small series of families linked to
chromosome 7q33, which has revealed a number of
potential candidate genes [5]. 
In this report we have identified a small family that
is characterized by stomach cancer and the presence
of chordoma in one of three siblings all of whom have
succumbed to malignancy. 
Patients and methods
The family history of disease is as follows: The
proband presented at the age of 56 years with a poorly
differentiated adenocarcinoma of the cecum without
the presence of adenomatous polyps. At the time of
excision the tumour had metastasized to three lymph
nodes. The patient was found to have widespread
metastatic disease at the age of 60 years and died one
year later. The only other remarkable finding with
respect to this patient was the congenital aplasia of the
left thigh. The family history of the proband revealed
a history of gastrointestinal cancer (see Fig. 1). 
The father of the proband was diagnosed with
stomach cancer at the age of 67 years. The tumour
was diagnosed as an undifferentiated mucinous
carcinoma with signet ring cells which had at the time
of surgery already spread to the liver. 
The eldest brother of the patient was diagnosed at
the age of 7 1/2 years with a malignant chordoma at
the base of his skull and died soon after. The tumour
was situated between the clivus and pons which gave
rise to typical neurological signs. The tumour had
impinged on the optic nerve resulting in severe atrophy,
especially on the right side. In addition there were
multiple liver metastases. 
The second brother was diagnosed with
adenocarcinoma of the stomach originating in the
cardia. The tumour was an undifferentiated mucinous
type interspersed with signet ring cells, similar to that
of the father. At the time of diagnosis the disease was
found to have become widespread with metastases to
the vertebra, liver, adrenals and lungs. 
DHPLC analysis
The entire coding sequences of hMSH2, hMLH1
and E-cadherin including the intron/exon boundaries
were screened for mutations by DHPLC analysis. Any
unusual conformers were further assessed by direct
DNA sequencing. 
Polymerase chain reaction (PCR) amplification for
DHPLC analysis was performed using primers specific for
hMSH2 and hMLH1 as described previously
(Holinski-Feder et al 2001). The reaction consisted of 1.0
µM each primer, 1U Platinum Taq (Gibco-BRL), 2-5 mM
MgCl2 and 200 µM each dNTP. 
PCR amplification was achieved by an initial
denaturation at 94°C for 5 min followed by 14 cycles
of 94°C for 1 min, 7°C touchdown range for 1.5 min
and 72°C for 2 min, then 20 cycles using an annealing
temperature 0.5°C lower than the bottom of the
touchdown range. The annealing step was performed
as a touchdown protocol with a 7°C range, decreasing
0.5°C/cycle over 14 cycles. This was followed by a final
extension step at 72°C for 10 min, a final denaturation
step at 95°C for 5 min and a slow annealing step from
95°C to 65°C over 30 min to promote heteroduplex
Fig. 1. Pedigree of the family. St = stomach cancer; Ch = chordoma;
CRC = colorectal cancer. Squares represent males, circles females
St
StCh CRC
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formation. The PCR was performed on a PCR express
(Hybaid) instrument equipped with a heated lid to avoid
the use of mineral oil. 
DHPLC analysis was performed using a Varian Helix
system (Varian Inc., Walnut Creek, CA). PCR products
(2-5 µl) were injected directly into a DNA Eclipse (Hewlett
Packard) or Helix (Varian) column and eluted from the
column using an increasing acetonitrile gradient and
a column oven temperature suitable for each exon of
hMSH2, hMLH1 and E-cadherin (actual temperatures
available on request). Heteroduplexes formed during
PCR of a heterozygote sample were detected as an
additional peak eluting before the homoduplex peak.
The detection of heteroduplexes was made simpler
with the use of DHPLC review software supplied from
Varian. The predicted melting temperatures of the
double stranded DNA products were obtained by
using the DHPLC-MELT program available from
http://www.insertion.stanford.edu/melt.html (for details
see Tables 1a and 1b). 
For each segment a negative control fragment
(amplified from DNA isolated from a normal healthy
donor who had no family history of disease) was run
through the denaturing column at the non-denaturing
temperature of 50°C. The 50°C peak profile was then
compared to the Stanford melting temperature profile of
the respective fragment as well as three 1°C increments
on either side of predicted melting temperature. Partially
denatured conditions were established when a shift in
retention time of at least or equal to 30 seconds across
a 1°C increment range was made. The optimal melting
temperature was always taken as the higher temperature,
under partially denaturing conditions that did not exhibit
profile degradation. 
DNA sequencing
All heteroduplexes were subject to DNA sequencing
to determine the precise genetic change on a semi-
automated sequencing unit (model 310, Perkin-Elmer
Applied Biosystems Division, Foster City, CA) using
dideoxy. Sequencing of the PCR products was
performed using version 1 BIGDYE dideoxy sequencing
Ready Rxn kit (Perkin-Elmer, Foster City, CA). 
Results
The family depicted in Fig. 1 conforms to the
Amsterdam II criteria where other epithelial
malignancies can replace colorectal cancer. The
presence of two gastric cancers is unusual and could
be suggestive of familial gastric cancer due to
mutations in E-cadherin. 
There was no material available for
immunohistochemistry or microsatellite instability testing.
A DNA sample was available from the proband which
was subjected to mutation analysis. Since the family
adhered to the Amsterdam II criteria initially hMSH2 and
hMLH1 mutation analysis was undertaken. No mutations
were identified in the coding sequence of either hMSH2
or hMLH1 including the intron/exon boundaries. 
Since there were two individuals diagnosed with
gastric cancer a further mutation screen was
undertaken in the E-cadherin gene but no deleterious
changes were identified. 
Discussion
The failure to identify mutations in hMLH1, hMSH2
or E-cadherin suggests that there are likely to be other
genetic factors underlying the disease in this family.
There is nevertheless, the possibility that a mutation
was missed in one of these three genes since deletion
analysis was not undertaken nor was it possible to do
so as there was insufficient genetic material to allow
this to occur. Furthermore, since the patients
succumbed to their diseases several decades ago it
is unlikely that immunohistochemistry or microsatellite
instability testing could be performed to assess the
probability of this family belonging to the entity of
HNPCC. E-cadherin was a likely candidate by virtue
of the presence of signet ring cells within the two
stomach cancers. 
There remain several possibilities with respect to
what may have occurred within this small family. First,
it remains possible that this is indeed an HNPCC family
not only because there may be mutations in either
hMLH1 or hMSH2 but also we did not examine hMSH6
or hPMS2. The hPMS2 gene remains a likely candidate
as it has been associated with recessively inherited
cases of Turcot’s syndrome [9]. In addition, hPMS2
resides on chromosome 7 and is surrounded by
pseudogenes, some of which are expressed albeit at
much lower levels than wild type hPMS2. Since a new
locus for chordoma has also been identified on
chromosome 7 there remains the possibility that in this
family these two findings are not unrelated.
Unfortunately, we may never know the answer to this
since there is insufficient remaining material to study
from the proband and the tumour samples taken from
the other family members are no longer available. With
respect to the father of the proband we do not know if
the congenital aplasia of the left thigh was related to
disease in this family. 
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In summary, this family represents not only
a challenge with respect to the identification of
a genetic predisposition but also, if the family members
were alive today, for genetic counselling. 
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